Gallacher Capital Management LLC Purchases Shares of 5,756 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Gallacher Capital Management LLC acquired a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 5,756 shares of the specialty pharmaceutical company’s stock, valued at approximately $223,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Principal Securities Inc. bought a new position in shares of Collegium Pharmaceutical during the 4th quarter worth about $40,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Collegium Pharmaceutical by 320.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock worth $116,000 after acquiring an additional 2,877 shares during the period. Assetmark Inc. lifted its holdings in shares of Collegium Pharmaceutical by 25.5% during the 4th quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock worth $168,000 after acquiring an additional 1,108 shares during the period. Johnson Investment Counsel Inc. bought a new position in shares of Collegium Pharmaceutical during the 4th quarter worth about $257,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Collegium Pharmaceutical by 28.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,841 shares of the specialty pharmaceutical company’s stock worth $272,000 after acquiring an additional 1,967 shares during the period.

Analysts Set New Price Targets

COLL has been the subject of a number of analyst reports. Piper Sandler downgraded shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price objective for the company. in a report on Friday, May 10th. Needham & Company LLC downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Jefferies Financial Group upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and increased their target price for the stock from $41.00 to $44.00 in a research report on Friday, June 7th. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $40.75.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock traded down $0.02 during mid-day trading on Friday, reaching $31.86. 51,095 shares of the stock were exchanged, compared to its average volume of 456,772. The company has a market cap of $1.04 billion, a price-to-earnings ratio of 13.28 and a beta of 0.93. The company has a current ratio of 1.21, a quick ratio of 1.14 and a debt-to-equity ratio of 1.98. The firm has a 50-day simple moving average of $33.04 and a 200 day simple moving average of $34.45. Collegium Pharmaceutical, Inc. has a fifty-two week low of $20.95 and a fifty-two week high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). The firm had revenue of $144.92 million for the quarter, compared to analyst estimates of $147.04 million. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. On average, sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.57 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Scott Dreyer sold 56,807 shares of the business’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the completion of the sale, the executive vice president now directly owns 105,902 shares of the company’s stock, valued at $3,598,549.96. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, EVP Scott Dreyer sold 56,807 shares of the business’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the completion of the transaction, the executive vice president now owns 105,902 shares in the company, valued at $3,598,549.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Garen G. Bohlin sold 28,985 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total transaction of $936,215.50. Following the transaction, the director now owns 44,775 shares of the company’s stock, valued at approximately $1,446,232.50. The disclosure for this sale can be found here. Insiders sold a total of 105,502 shares of company stock valued at $3,540,796 over the last ninety days. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.